Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to investigate the impact of high-intensity interval training (HIIT) program on body composition, hematological parameters, plasma volume variations (PVV), muscle damage markers, and aerobic capacity in overweight/obese adolescent girls. The main question it aims to answer is: Does HIIT reduce risk factors associated obesity diseases by modulating body composition and hematological parameters and increasing PVV? Researchers will compare HIIT (designed to the experimental group) to nontraining intervention (designed to the control group) to see if the training program works to enhance physiological health and reduce risk factors associated with obesity in this population. Participants in the experimental (HIIT group) group will: underwent HIIT at 90-105% maximal aerobic speed (MAS), three times a week.
Participants in control group will : not perform any physical training and maintain their usual daily activities.
Obesity during adolescence is linked to adverse changes in body composition, aerobic fitness, and blood health. High-intensity interval training (HIIT) is a promising strategy to improve these outcomes. However, its effects on hematological markers, plasma volume, and muscle damage in overweight/obese adolescent girls remain unclear. This study aimed to investigate the effects of HIIT on body composition, hematological parameters, plasma volume variations (PVV), muscle damage markers, and aerobic capacity in this population.Twenty-eight overweight/obese girls (16.21±0.92) were randomly assigned to a HIIT group (n=14) or control group (n=14). The 10-week HIIT protocol consisted of 4×6×15s running at 90-105% maximal aerobic speed (MAS) with 15s of active recovery at 50% MAS (3 sessions/week). Pre/post assessments included body composition, hematological markers, muscle damage markers, and aerobic fitness. Plasma volume was estimated post-intervention in both group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High-intensity interval training group | Experimental | High-intensity interval training group performed four series of 15-second runs at 90-105% of the maximal aerobic speed (MAS) interspersed with 15 seconds of active recovery at 5O% MAS. |
|
| Control group | No Intervention | No training intervention was intended for the control group. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High intensity interval training | Behavioral | HIIT protocol was performed three times per week over a 10-week period, totaling 30 sessions. HIIT sessions included: (1) a standardized warm-up of five minutes of continuous jogging at 50%MAS, followed by five minutes of dynamic mobility and activation drills such as high-knee skips, high-knee running, and butt kicks. (2) a HIIT training session, consisted of four series of 15-second runs at 90-105% of the maximal aerobic speed (MAS) interspersed with 15 seconds of active recovery and (3) a cool-down of five minutes of static stretching. |
| Measure | Description | Time Frame |
|---|---|---|
| Erythrocytes | Blood levels of erythrocytes were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). | At baseline and at week 11 (end of intervention period). |
| Hemoglobin | Blood levels of hemoglobin were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). | At baseline and at week 11 (end of intervention period). |
| Hematocrit | Blood levels of hematocrit were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). | At baseline and at week 11 (end of intervention period). |
| Mean corpuscular volume | Blood levels of mean corpuscular volume were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). | At baseline and at week 11 (end of intervention period). |
| Mean corpuscular hemoglobin content | Blood levels of mean corpuscular hemoglobin content were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). | At baseline and at week 11 (end of intervention period). |
| Mean hemoglobin concentration | Blood levels of mean hemoglobin concentration were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Female
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wissal abassi, Dr | Research Unit "Sport Sciences, Health and Movement"(UR22JS01) High Institute of Sport and Physical Education of Kef, University of Jendouba, 7100 Kef, Tunisia. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| High Institute of Sports and Physical Education of Kef | El Kef | Boulifa | 7100 | Tunisia |
For confidentiality reasons, all data from this study are available upon request.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000072696 | High-Intensity Interval Training |
| ID | Term |
|---|---|
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| At baseline and at week 11 (end of intervention period) |
| Creatine kinase | Serum concentrations of creatine kinase are measured from a blood sample (5 ml) using a Beckman Coulter AU480 Chemistry Analyzer (France). | At baseline and at week 11 (end of intervention period). |
| Lactate dehydrogenase | Serum concentrations of lactate dehydrogenase are measured from a blood sample (5 ml) using a Beckman Coulter AU480 Chemistry Analyzer (France). | At baseline and at week 11 (end of intervention period). |
| Plasma volume variations | Plasma volume variations (PVV) was calculated based on measured hematocrit (Ht) and hemoglobin (Hb) values according to the method developed by Costill and Fink (1974). %PVV=100 ×[(HbA/HbB) ×(100 - HtB) / (100 - HtA)] - 1, where 0 is the value measured before training program and 1 is the value measured after training program. | Plasma volume variations (PVV) was calculated at week 11 (end of intervention period) under two conditions (High intensity interval training and No training intervention [control group] ). |
| Body weight | Body weight (kg) was recorded , with barefoot and lightly dressed subjects, using an electronic scale (Tanita BC-533, Tokyo, Japan). | At baseline and at week 11 (end of intervention period). |
| Height | Height (m) was determined using a standard stadiometer (Holtain Ltd., UK). | At baseline |
| Body fat | Body fat (%) was recorded using an electronic scale (Tanita BC-533, Tokyo, Japan). | At baseline and at week 11 (end of intervention period) |
| Body mass index | Body mass index (kg/m²) was calculated as weight (kg) divided by height squared (m²). | At baseline and at week 11 (end of intervention period). |
| Waist circumference | Waist circumference (cm) was measured to the nearest 0.1 cm using a non-deformable anthropometric tape, placed horizontally at the midpoint between the inferior margin of the last palpable rib and the superior border of the iliac crest, with the participant standing upright and breathing normally. | At baseline and at week 11 (end of intervention period). |
| Maximal aerobic speed | Maximal aerobic speed was determined using the Vameval test (Cazorla,1990). | At baseline and at week 11 (end of intervention period). |
| Maximal oxygen consumption (VO2max) | Maximal oxygen consumption (VO2max) were determined using the Vameval test (Cazorla,1990). | At baseline and at week 11 (end of intervention period). |
| Maximal heart rate (HRmax) | Maximal heart rate maximum (HRmax) was recorded at the final stage of the Vameval test (Cazorla,1990) using a Polar heart rate monitor (Polar S810, Kempele, Finland). | At baseline and at week 11 (end of intervention period). |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009142 |
| Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |